Have any questions? 706-721-6582 or cts@augusta.edu
- Clozapine versus Olanzapine for the Treatment of Co-Morbid Psychotic and Substance Use Disorders
Clinical Trial
Clozapine versus Olanzapine for the Treatment of Co-Morbid Psychotic and Substance Use Disorders
The purpose of this study is to determine whether patients treated with clozapine are more likely to remain in treatment, display greater reductions in features of psychosis and have fewer positive urine drug screens throughout the 12-week duration of the study than patients treated with olanzapine.
- Antipsychotic
- Bipolar
- Clozapine
- Depression
- Olanzapine
- Psychotic Disorder
- Schizophrenia
- Substance Use Disorder
Eligibility Criteria
- Inclusion 18-60 years of age, male or female (post-menopausal, surgically sterilized, or receiving either one of the listed contraception - depot contraceptive, Intrauterine device, or implanted hormonal contraceptive), who meet DSM-V criteria for schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, depression with psychotic features, or delusional disorder, and have ratings of Moderate or greater on at least one of the Brief Psychiatric Rating Scale psychosis items, who meet DSM-V criteria for at least one of alcohol, marijuana, cocaine, stimulant, or opioid use disorder, and have an admission urine drug screen positive for at least one of these substances, who have a stable living situation (family or supervised living, e.g. personal care home) to return to after release into the community, and who provide signed informed consent to participate (after testing for comprehension). Patients will be excluded who meet any of the following exclusion criteria: failure to respond or tolerate clozapine or olanzapine Logistics that prevent outpatient follow-up at Augusta University psychiatry outpatient clinic at Stoney Building or Serenity Behavioral Health Adult Outpatient services
RESEARCH. INNOVATION. DISCOVERY.